Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2897593 | 0.85 | TNF (0.57) | MAPK1TNFNOD1LMNAALDH1A1 | |
| SCHEMBL2905228 | 0.84 | LMNA (0.39) | MAPK1TNFNOD1LMNAALDH1A1 | |
| SCHEMBL2897597 | 0.81 | PIK3CA (0.41) | LMNAALDH1A1SMN1; SMN2HDAC6HDAC4 | |
| SCHEMBL2903277 | 0.79 | ALDH1A1 (0.35) | MAPK1TNFNOD1LMNAALDH1A1 | |
| SCHEMBL6360222 | 0.78 | TNF (0.41) | MAPK1TNFNOD1LMNAALDH1A1 | |
| SCHEMBL3384963 | 0.78 | ESR1 (0.57) | MAPK1TNFNOD1LMNAALDH1A1 | |
| SCHEMBL2368714 | 0.76 | ESR1 (0.40) | MAPK1TNFNOD1LMNAALDH1A1 | |
| SCHEMBL2368659 | 0.75 | ESR1 (0.39) | MAPK1TNFNOD1LMNAALDH1A1 | |
| SCHEMBL2368960 | 0.75 | ESR1 (0.39) | MAPK1TNFNOD1LMNAALDH1A1 | |
| SCHEMBL2900101 | 0.75 | TNF (0.69) | MAPK1TNFNOD1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879899-B1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-08-04 | — | — | EP | claimed |
| US-7576212-B2 | Thieno[2,3-B] pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2009-08-18 | — | — | US | claimed |
| EP-1879899-A1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2008-01-23 | — | — | EP | claimed |
| US-20060183768-A1 | Compounds | XENTION DISCOVERY LTD. (GB) | 2006-08-17 | — | — | US | claimed |
| WO-2006061642-A1 | COMPOUNDS | XENTION DISCOVERY LIMITED (GB) | 2006-06-15 | — | — | WO | claimed |
| US-8193215-B2 | Thieno[2 3-b]pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2012-06-05 | — | — | US | disclosed |
| EP-1879899-B1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2010-08-04 | — | — | EP | disclosed |
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | XENTION LIMITED (GB) | 2010-02-18 | — | — | US | disclosed |
| US-7576212-B2 | Thieno[2,3-B] pyridines as potassium channel inhibitors | XENTION LIMITED (GB) | 2009-08-18 | — | — | US | disclosed |
| EP-1879899-A1 | THIENOPYRIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | Xention Discovery Limited (GB) | 2008-01-23 | — | — | EP | disclosed |
| US-20060183768-A1 | Compounds | XENTION DISCOVERY LTD. (GB) | 2006-08-17 | — | — | US | disclosed |
| WO-2006061642-A1 | COMPOUNDS | XENTION DISCOVERY LIMITED (GB) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041695-A1 | Thieno[2,3-b]pyridines as Potassium Channel Inhibitors | SCN8A, SCN1B, SCN2B | MAPK1 1630/4885TNF 4358/4885NOD1 626/4885 |
| US-20060183768-A1 | Compounds | SCN7A, CBR3, SCN8A | MAPK1 2620/4885TNF 3698/4885NOD1 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.